Skip to main content
Rybelsus is a tablet form of semaglutide. It is licensed in the European Union, but only for one thing: controlling blood sugar in adults with type 2 diabetes. It is not licensed in the EU as a weight-loss medicine.
People taking Rybelsus for diabetes often lose some weight as a side effect, and that is where its reputation as a weight-loss pill comes from. Prescribing it purely to lose weight is off-label — used outside what EU regulators have assessed and approved — so the EU-assessed benefit-risk balance for that use has not been established.

​
What it is

Rybelsus contains oral semaglutide, a copy of the gut hormone GLP-1 taken as a daily tablet rather than an injection. It has been authorised for use in the EU since 3 April 2020, for adults with type 2 diabetes. Any place it takes in a weight-management pathway is an individual doctor-led decision and may be off-label.
A separate, higher-dose oral semaglutide tablet (25 mg) was authorised by the European Commission for weight management in July 2026. That is a different product from Rybelsus — if you’re looking for a semaglutide tablet specifically for weight, a doctor should decide which one, if either, applies to you.

​
How it works

Semaglutide activates GLP-1 receptors, supporting glucose-dependent insulin release, reducing glucagon, and slowing stomach emptying. Appetite may also decrease as a result.

Tablet formulation

Semaglutide without an injection, but it requires precise fasting administration.

Gradual escalation

Starting low helps the body adapt before a maintenance dose is considered.

Metabolic review

Glucose control, appetite, weight and adverse effects are reviewed together.

​
What the studies reported

The pivotal trial, PIONEER 4, was a type 2 diabetes trial whose main purpose was to measure blood-sugar control (ClinicalTrials.gov · NCT02863419). Weight change was a secondary measurement in people with diabetes — the trial was not a test of Rybelsus as a weight-loss treatment, and Rybelsus has no EU weight-management indication. A readout is not the same as peer-reviewed publication; results here are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.

​
How to take it

1

Take on an empty stomach

First thing in the morning, at least 8 hours after your last meal. Swallow the tablet whole with a sip of water — no more than 120 ml. Do not split, crush or chew it.
2

Wait 30 minutes before eating

Wait at least 30 minutes before eating, drinking anything else, or taking other medications, so the tablet is absorbed properly.
3

Take it at the same time each day

Consistency helps maintain steady levels. If a dose is missed, skip it and take the next one at the usual time — never take two doses together.

​
Dose schedule

1

Start · 1.5 mg once daily for one month

The starting dose while the body adjusts to the medication.
2

Step up · 4 mg once daily if appropriate

Remain at this level for at least 30 days.
3

Review · Consider 9 mg only after at least one month

Full maintenance dose for ongoing treatment. The doctor reassesses every 3 months.

​
What has been reported

Effects are usually mild to moderate and settle over time, most often in the first weeks. Nausea often improves within 1–2 weeks; smaller meals eaten slowly, and avoiding fatty or fried food, can help.
Store below 25°C in the original packaging, protected from light and moisture, and do not use it after the expiry date.

​
Managing side effects

Nausea is very common in the first weeks. Eating smaller meals, avoiding fatty or fried foods, and eating slowly can help. Drinking plenty of water (6 to 8 glasses a day) and including fibre-rich foods like vegetables and whole grains may also help. Some people feel tired in the first weeks, but this usually passes.

​
Common questions

The Rybelsus product information does not list a specific interaction with alcohol. However, alcohol can affect blood-sugar control, and the reviewing doctor discusses this as part of the consultation.
Semaglutide begins to act from the first dose, but appetite changes may not be noticeable for 2 to 4 weeks. Weight loss is assessed at 3 months, and the doctor reviews progress quarterly.
Skip the missed dose and take the next one at the usual time. Do not take two doses together. Consistency helps maintain steady levels, so a daily routine is important.
Rybelsus is authorised in the EU only for type 2 diabetes. Prescribing it purely for weight loss is off-label, so the EU-assessed benefit-risk balance for that use has not been established. If you are looking for a semaglutide tablet specifically for weight management, a higher-dose oral semaglutide (25 mg) was authorised in the EU in July 2026 — that is a different product from Rybelsus.
Rybelsus and injectable semaglutide contain the same active substance but at different doses and with different absorption profiles. The reviewing doctor decides whether switching is clinically appropriate based on your history and the indication.

​
Who it is not suitable for

  • You are pregnant, breastfeeding or planning pregnancy
  • A history of serious semaglutide reaction, or an unresolved pancreatic or gastrointestinal concern, makes it unsuitable
Contact your doctor for severe abdominal pain that does not go away, persistent vomiting, signs of an allergic reaction (rash, itching, swelling), or any symptom that worries you.

​
How Hi-Doctor handles it

A licensed doctor reviews your case, not an algorithm. The indication, regimen and follow-up depend on your medical history — prescribing is never automatic, and it is always reviewed against the authorised indication above. See the full treatment areas Hi-Doctor covers and how the review process works. The medical consultation fee is set out on pricing; the medicine itself is paid separately at a pharmacy. For injectable semaglutide options, see Wegovy and Ozempic; for other weight-management options, see Mounjaro and orlistat.
The full Rybelsus treatment guide — swallowing technique, day-by-day dosing and storage in more detail — is published at hi-doctor.ai/guides/rybelsus.

​
Start a consultation

Weight-loss consultation

Answer the weight-loss questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.